Episurf Medical: Q3 report a non-event - DNB

The company reported its Q3 earnings (loss) on 29 October, but the key information was already known (released with the capital raise in mid-October), so the report was a non-event. We still like the progress being made, with a broadening of the product pipeline, more clinical documentation being published, and now also a more solid financial position. We reiterate our fair value of SEK3.5–9.5.

Länk till analysen i sin helhet: https://www.dnb.no/seg-fundamental/fundamentalweb/GetReportSpon.aspx?file=CMPSP_184296.pdf